Cargando…

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2

OBJECTIVES: Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, Gururaj Rao, Kaduskar, Ojas, Deshpande, Ketki, Bhatt, Vaishali, Yadav, Pragya, Gurav, Yogesh, Potdar, Varsha, Khutwad, Kirti, Vidhate, Shankar, Salunke, Asha, Patil, Chetan, Shingade, Snehal, Jarande, Kajal, Tilekar, Bipin, Salvi, Pavan, Patsuthe, Sudhir, Dange, Varsha, Kumar, Sudeep, Gurav, Shilpa, Chate, Sadhana, Abraham, Priya, Sapkal, Gajanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447547/
https://www.ncbi.nlm.nih.gov/pubmed/34543771
http://dx.doi.org/10.1016/j.ijid.2021.09.024
_version_ 1784569038624522240
author Deshpande, Gururaj Rao
Kaduskar, Ojas
Deshpande, Ketki
Bhatt, Vaishali
Yadav, Pragya
Gurav, Yogesh
Potdar, Varsha
Khutwad, Kirti
Vidhate, Shankar
Salunke, Asha
Patil, Chetan
Shingade, Snehal
Jarande, Kajal
Tilekar, Bipin
Salvi, Pavan
Patsuthe, Sudhir
Dange, Varsha
Kumar, Sudeep
Gurav, Shilpa
Chate, Sadhana
Abraham, Priya
Sapkal, Gajanan
author_facet Deshpande, Gururaj Rao
Kaduskar, Ojas
Deshpande, Ketki
Bhatt, Vaishali
Yadav, Pragya
Gurav, Yogesh
Potdar, Varsha
Khutwad, Kirti
Vidhate, Shankar
Salunke, Asha
Patil, Chetan
Shingade, Snehal
Jarande, Kajal
Tilekar, Bipin
Salvi, Pavan
Patsuthe, Sudhir
Dange, Varsha
Kumar, Sudeep
Gurav, Shilpa
Chate, Sadhana
Abraham, Priya
Sapkal, Gajanan
author_sort Deshpande, Gururaj Rao
collection PubMed
description OBJECTIVES: Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein specific IgG and neutralizing antibody (NAb) responses in COVID-19 patients up to 8 months and its correlation with diverse disease spectrum. METHODS: During the first wave of the SARS-CoV-2 pandemic, from 284 COVID-19 patients, 608 samples were collected up to 8 months post infection. The patients were categorized as asymptomatic, symptomatic and severe. The N and SRBD IgG and NAb titers were evaluated and correlated with clinical data. RESULTS: A steep increase in antigen specific antibody titers was observed till 40 days post onset of the disease (POD), followed by a partial decline till 240 days. Severe disease was associated with a stronger SRBD IgG response and higher NAb titers. The persistence of antibody response was observed in 76% against N, 80% against SRBD and 80% for NAbs of cases up to 8 months POD. CONCLUSION: RBD and N protein specific IgG persisted till 240 days POD which correlated with NAb response, irrespective of individual`s symptomatic status indicating overall robust protection against re-infection.
format Online
Article
Text
id pubmed-8447547
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-84475472021-09-17 Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2 Deshpande, Gururaj Rao Kaduskar, Ojas Deshpande, Ketki Bhatt, Vaishali Yadav, Pragya Gurav, Yogesh Potdar, Varsha Khutwad, Kirti Vidhate, Shankar Salunke, Asha Patil, Chetan Shingade, Snehal Jarande, Kajal Tilekar, Bipin Salvi, Pavan Patsuthe, Sudhir Dange, Varsha Kumar, Sudeep Gurav, Shilpa Chate, Sadhana Abraham, Priya Sapkal, Gajanan Int J Infect Dis Article OBJECTIVES: Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein specific IgG and neutralizing antibody (NAb) responses in COVID-19 patients up to 8 months and its correlation with diverse disease spectrum. METHODS: During the first wave of the SARS-CoV-2 pandemic, from 284 COVID-19 patients, 608 samples were collected up to 8 months post infection. The patients were categorized as asymptomatic, symptomatic and severe. The N and SRBD IgG and NAb titers were evaluated and correlated with clinical data. RESULTS: A steep increase in antigen specific antibody titers was observed till 40 days post onset of the disease (POD), followed by a partial decline till 240 days. Severe disease was associated with a stronger SRBD IgG response and higher NAb titers. The persistence of antibody response was observed in 76% against N, 80% against SRBD and 80% for NAbs of cases up to 8 months POD. CONCLUSION: RBD and N protein specific IgG persisted till 240 days POD which correlated with NAb response, irrespective of individual`s symptomatic status indicating overall robust protection against re-infection. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-11 2021-09-17 /pmc/articles/PMC8447547/ /pubmed/34543771 http://dx.doi.org/10.1016/j.ijid.2021.09.024 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Deshpande, Gururaj Rao
Kaduskar, Ojas
Deshpande, Ketki
Bhatt, Vaishali
Yadav, Pragya
Gurav, Yogesh
Potdar, Varsha
Khutwad, Kirti
Vidhate, Shankar
Salunke, Asha
Patil, Chetan
Shingade, Snehal
Jarande, Kajal
Tilekar, Bipin
Salvi, Pavan
Patsuthe, Sudhir
Dange, Varsha
Kumar, Sudeep
Gurav, Shilpa
Chate, Sadhana
Abraham, Priya
Sapkal, Gajanan
Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
title Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
title_full Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
title_fullStr Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
title_full_unstemmed Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
title_short Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
title_sort longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447547/
https://www.ncbi.nlm.nih.gov/pubmed/34543771
http://dx.doi.org/10.1016/j.ijid.2021.09.024
work_keys_str_mv AT deshpandegururajrao longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT kaduskarojas longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT deshpandeketki longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT bhattvaishali longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT yadavpragya longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT guravyogesh longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT potdarvarsha longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT khutwadkirti longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT vidhateshankar longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT salunkeasha longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT patilchetan longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT shingadesnehal longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT jarandekajal longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT tilekarbipin longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT salvipavan longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT patsuthesudhir longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT dangevarsha longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT kumarsudeep longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT guravshilpa longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT chatesadhana longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT abrahampriya longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2
AT sapkalgajanan longitudinalclinicoserologicalanalysisofantinucleocapsidandantireceptorbindingdomainofspikeproteinantibodiesagainstsarscov2